WO2004022717A3 - Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire - Google Patents
Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire Download PDFInfo
- Publication number
- WO2004022717A3 WO2004022717A3 PCT/US2003/027976 US0327976W WO2004022717A3 WO 2004022717 A3 WO2004022717 A3 WO 2004022717A3 US 0327976 W US0327976 W US 0327976W WO 2004022717 A3 WO2004022717 A3 WO 2004022717A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- col
- antibody
- humanized col
- humanized
- carcinoembryonic antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003270369A AU2003270369A1 (en) | 2002-09-05 | 2003-09-05 | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40870302P | 2002-09-05 | 2002-09-05 | |
US60/408,703 | 2002-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004022717A2 WO2004022717A2 (fr) | 2004-03-18 |
WO2004022717A3 true WO2004022717A3 (fr) | 2004-09-02 |
Family
ID=31978660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/027976 WO2004022717A2 (fr) | 2002-09-05 | 2003-09-05 | Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003270369A1 (fr) |
WO (1) | WO2004022717A2 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2005112564A2 (fr) * | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
AU2005322869B2 (en) * | 2004-12-30 | 2011-05-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Framework residue substituted humanized COL-1 antibodies and their use |
WO2007090596A1 (fr) * | 2006-02-06 | 2007-08-16 | Medizinische Universität Wien | Vaccin et mimotopes d'antigènes dirigés contre les maladies cancéreuses associées à l'antigène |
ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333405B1 (en) * | 1996-10-31 | 2001-12-25 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
-
2003
- 2003-09-05 AU AU2003270369A patent/AU2003270369A1/en not_active Abandoned
- 2003-09-05 WO PCT/US2003/027976 patent/WO2004022717A2/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333405B1 (en) * | 1996-10-31 | 2001-12-25 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
Non-Patent Citations (3)
Title |
---|
KASS E.S. ET AL: "Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer", CANCER RESEARCH, vol. 62, 1 September 2002 (2002-09-01), pages 5049 - 5057, XP002978237 * |
RABEN D. ET AL: "Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene", GENE THERAPY, vol. 3, 1996, pages 567 - 580, XP002061094 * |
YU B.B. ET AL: "Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics", JOURNAL OF CLINICAL ONCOLOGY, vol. 14, no. 6, June 1996 (1996-06-01), pages 1798 - 1809, XP002978417 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
Also Published As
Publication number | Publication date |
---|---|
WO2004022717A2 (fr) | 2004-03-18 |
AU2003270369A8 (en) | 2004-03-29 |
AU2003270369A1 (en) | 2004-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004022717A3 (fr) | Variants tres faiblement immunogenes de l'anticorps humanise col-1 contre l'antigene carcino-embryonnaire | |
WO2005112564A3 (fr) | Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation | |
NZ593068A (en) | IL-18 antibody | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
NZ547157A (en) | Interferon Alpha Antibodies and their uses | |
JP2004527212A5 (fr) | ||
HK1076128A1 (en) | Humanized collagen antibodies and related methods | |
WO2003100008A3 (fr) | Anticorps anti-igfr humain neutralisant | |
WO1998050433A3 (fr) | Anticorps monoclonaux humains contre le recepteur du facteur de croissance epidermique | |
WO2003068801A3 (fr) | Variantes d'anticorps a vitesses d'association d'antigene accelerees | |
EP2112166A3 (fr) | Anticorps monoclonaux humaines pour CTLA-4 | |
WO2004050683A8 (fr) | Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation | |
ITRM20030601A1 (it) | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. | |
GEP20074222B (en) | Antibodies to cd40 | |
WO2003057857A3 (fr) | Anticorps diriges contre les pdgfd et utilisations | |
WO2005003170A3 (fr) | Fragments d'anticorps modifies | |
WO2004001381A3 (fr) | Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible | |
AU2001289145A1 (en) | Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof | |
WO2002072832A3 (fr) | Molecules de liaison therapeutiques | |
WO2004065569A3 (fr) | Anticorps multifonctionnels | |
WO1999003987A3 (fr) | Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie | |
WO2002074251A3 (fr) | Traitement par anticorps monoclonal du cancer du pancreas | |
DK1167389T3 (da) | Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf | |
WO2005047328A3 (fr) | Anticorps diriges contre l'inhibiteur de la protease des leucocytes secreteurs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |